TEVA — Teva Pharmaceutical Industries Limited (Stock)

Price: $39.01 · 1 day: -1.29% · 5 days: +1.25% · 1 month: +5.63% · YTD: +24.99%
As of 2026-09-23 20:00 UTC.

52-week range: $18.21 – $40.79 (currently at 92% of the range).

The read

TEVA is in an uptrend, momentum firm. $40 is the level overhead; $35.79 the first support below.

6 of 6 technical checks lean bullish.

• Price vs 50-day: above
• Price vs 200-day: above
• 50d vs 200d avg: above
• MACD: bullish
• RSI momentum: 59
• 5-day tape: +1.2%

Key levels

Indicators

Next earnings: 2026-11-03.

Latest TEVA news

• TEVA PHARMACEUTICAL INDUSTRIES LTD — Form 8-K: 1.01 Entry into a Material Agreement; 2.03 Creation of a Material Financial Obligation; 9.01 Financial Statements and Exhibits — Teva Pharmaceutical Industries Ltd. filed a Form 8-K with the SEC on September 16, 2026, disclosing the entry into a material agreement and the creation of a material financial obligation. The filing covers Items 1.01, 2 (SEC EDGAR, 2026-09-16)
• TEVA PHARMACEUTICAL INDUSTRIES LTD — Form 8-K: 8.01 Other Events — ```json { "summary": "Teva Pharmaceutical Industries filed a Form 8-K on September 14, 2026, disclosing other events under Item 8.01. The filing does not specify substantive details regarding the nature of the events d (SEC EDGAR, 2026-09-14)
• TEVA PHARMACEUTICAL INDUSTRIES LTD — Form 8-K: 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits — Teva Pharmaceutical Industries Ltd filed a Form 8-K with the SEC on September 11, 2026, covering Regulation FD Disclosure (Item 7.01), Other Events (Item 8.01), and Financial Statements and Exhibits (Item 9.01). The fili (SEC EDGAR, 2026-09-11)
• TEVA PHARMACEUTICAL INDUSTRIES LTD — Form 8-K: 8.01 Other Events; 9.01 Financial Statements and Exhibits — Teva Pharmaceutical Industries Ltd filed a Form 8-K with the SEC on September 3, 2026, covering Items 8.01 (Other Events) and 9.01 (Financial Statements and Exhibits). The filing does not disclose specific financial figu (SEC EDGAR, 2026-09-03)
• TEVA PHARMACEUTICAL INDUSTRIES LTD — Form 8-K: 3.03 Material Modification to Rights of Security Holders; 9.01 Financial Statements and Exhibits — ```json { "summary": "Teva Pharmaceutical Industries Ltd. filed a Form 8-K with the SEC on September 3, 2026, disclosing a material modification to the rights of security holders. The filing includes financial statemen (SEC EDGAR, 2026-09-03)
• Inflammatory Bowel Disease Market to Experience Strong Uptake During the Forecast Period (2026-2036), Driven by Development of Next-generation Therapies Targeting IL-23, TL1A, and S1P Pathways | DelveInsight — The global inflammatory bowel disease (IBD) market reached approximately USD 21 billion across the seven major markets (7MM) in 2025, with the United States representing the largest share. Market growth is expected to ac (PR Newswire, 2026-07-30)
• TEVA PHARMACEUTICAL INDUSTRIES LTD — Quarterly report (10-Q) — Teva Pharmaceutical Industries Ltd filed its SEC Form 10-Q for the second quarter of fiscal year 2026 on July 29, 2026. For the period ended June 30, 2026, the company reported revenue of $4.14 billion, a decrease of 1% (SEC EDGAR, 2026-07-29)
• TEVA PHARMACEUTICAL INDUSTRIES LTD — Form 8-K: 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits — Teva Pharmaceutical Industries Ltd filed a Form 8-K with the U.S. Securities and Exchange Commission on July 29, 2026. The filing was made under Items 2.02, Results of Operations and Financial Condition, and 9.01, Financ (SEC EDGAR, 2026-07-29)

Explore more

Interactive TEVA chart and analyst chat · Market terminal — movers, signals and news · Use MarketCrew inside Claude · Use MarketCrew inside ChatGPT · Top gainers today · 52-week highs